Active	Status	Sponsor type	Region	Phase	Filter
10 Active 2 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tunlametinib (HL-085) / Tianjin Binjiang Pharma
NCT06008119: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	Not yet recruiting	3	165	NA	Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab	Shanghai Kechow Pharma, Inc.	Colorectal Cancer Metastatic	12/26	12/26
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma	Recruiting	3	165	RoW	tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin	Shanghai Kechow Pharma, Inc.	Melanoma	09/27	09/27
NCT05217303: HL-085 in NRAS-mutated Advanced Melanoma	Completed	2	100	RoW	HL-085	Shanghai Kechow Pharma, Inc.	Melanoma	02/23	02/23
NCT05233332: Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)	Recruiting	2	186	RoW	HL-085, Vemurafenib, ZELBORAF	Shanghai Kechow Pharma, Inc.	CRC	01/24	07/24
NCT05263453: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation	Recruiting	2	104	RoW	HL-085, Vemurafenib	Shanghai Kechow Pharma, Inc.	Melanoma	09/24	12/24
NCT05900219: Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study	Not yet recruiting	2	75	NA	HL-085+Vemurafenib	Shanghai Kechow Pharma, Inc.	Non-small-cell Lung Cancer	09/25	09/25
NCT05331105: HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas	Recruiting	2	70	RoW	HL-085	Shanghai Kechow Pharma, Inc.	Neurofibromatosis 1, Plexiform Neurofibromas	10/25	10/28
NCT03973151: Study of HL-085 in NRAS Mutant Advanced Melanoma	Completed	1/2	42	RoW	HL-085	Shanghai Kechow Pharma, Inc.	Melanoma	01/21	01/21
NCT04683354: Study of HL-085 in Patients With Advanced Solid Tumor Tumors	Completed	1	28	US	HL-085	Kechow Pharma, Inc.	Solid Tumor, Adult	09/22	12/22
NCT03781219: A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation	Recruiting	1	45	RoW	HL-085, Vemurafenib, ZELBORAF	Shanghai Kechow Pharma, Inc.	Solid Tumor	12/23	12/23